[go: up one dir, main page]

EA201691421A1 - Гетероарилы и их применение - Google Patents

Гетероарилы и их применение

Info

Publication number
EA201691421A1
EA201691421A1 EA201691421A EA201691421A EA201691421A1 EA 201691421 A1 EA201691421 A1 EA 201691421A1 EA 201691421 A EA201691421 A EA 201691421A EA 201691421 A EA201691421 A EA 201691421A EA 201691421 A1 EA201691421 A1 EA 201691421A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heteroariles
application
vps34
proliferative
inflammatory
Prior art date
Application number
EA201691421A
Other languages
English (en)
Other versions
EA032458B1 (ru
Inventor
Инду Т. Бхаратхан
Крис Блэкберн
Джеффри П. Кьяварри
Джоухара Чуитар
Кортни А. Каллис
Натали Д`Амор
Пол Э. Флеминг
Кеннет М. Гигстад
Криста Э. Гипсон
Марио Жирар
Юнбо Ху
Дженис Ли
Ган Ли
Мансурех Резаеи
Майкл Д. Синтчак
Франсуа Суси
Стефен Г. Страуд
Трисия Дж. Вос
Тцзу-Тшинь Вонг
Хе Сюй
Тяньлинь Сюй
Инчунь Е
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53543363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691421(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA201691421A1 publication Critical patent/EA201691421A1/ru
Publication of EA032458B1 publication Critical patent/EA032458B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

В данном изобретении предложено соединение формулы Iи его фармацевтически приемлемые соли, где X, R, R, R, R, R, L, L, m и n описаны в описании. Такие соединения представляют собой ингибиторы VPS34 и поэтому могут быть пригодны для лечения пролиферативных, воспалительных или сердечно-сосудистых заболеваний.
EA201691421A 2014-01-14 2015-01-13 Гетероарилы и их применение EA032458B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927055P 2014-01-14 2014-01-14
US201462054742P 2014-09-24 2014-09-24
PCT/US2015/011191 WO2015108861A1 (en) 2014-01-14 2015-01-13 Heteroaryls and uses thereof

Publications (2)

Publication Number Publication Date
EA201691421A1 true EA201691421A1 (ru) 2017-05-31
EA032458B1 EA032458B1 (ru) 2019-05-31

Family

ID=53543363

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691421A EA032458B1 (ru) 2014-01-14 2015-01-13 Гетероарилы и их применение

Country Status (26)

Country Link
US (3) US9802960B2 (ru)
EP (1) EP3094325B1 (ru)
JP (1) JP6609258B2 (ru)
KR (1) KR20160122736A (ru)
CN (1) CN105916503B (ru)
AP (1) AP2016009368A0 (ru)
AU (1) AU2015206652A1 (ru)
BR (1) BR112016016289B1 (ru)
CA (1) CA2935867C (ru)
CL (1) CL2016001805A1 (ru)
CR (1) CR20160363A (ru)
DO (1) DOP2016000173A (ru)
EA (1) EA032458B1 (ru)
EC (1) ECSP16067303A (ru)
ES (1) ES2908042T3 (ru)
GE (1) GEP20196983B (ru)
IL (1) IL246755A0 (ru)
MX (1) MX2016009135A (ru)
MY (1) MY182908A (ru)
PE (1) PE20161313A1 (ru)
PH (1) PH12016501388A1 (ru)
SG (1) SG11201604820XA (ru)
TN (1) TN2016000270A1 (ru)
TW (1) TWI662024B (ru)
UY (1) UY35951A (ru)
WO (1) WO2015108861A1 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2809869C1 (ru) * 2020-02-13 2023-12-19 Генфлит Терапьютикс (Шанхай) Инк. Соединение на основе дигидронафтиридинона, и способ его получения, и его применение в медицине
US12227498B2 (en) 2018-08-27 2025-02-18 Daewoong Pharmaceutical Co., Ltd. Heterocyclic amine derivative and pharmaceutical composition comprising same

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104230922B (zh) 2013-06-19 2016-12-28 中国科学院上海药物研究所 一类五元杂环并吡啶类化合物及其制备方法和用途
EP3094326A4 (en) 2014-01-14 2017-07-26 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
ES2908042T3 (es) 2014-01-14 2022-04-27 Takeda Pharmaceuticals Co Heteroarilos y usos de los mismos
CN108617166B (zh) * 2015-10-21 2022-05-17 大冢制药株式会社 蛋白激酶抑制剂苯并内酰胺化合物
HUE050863T2 (hu) 2016-02-19 2021-01-28 Sprint Bioscience Ab Rák és cukorbetegség kezelésére alkalmazható 6-aril-4-(morfolin-4-il)-1H-piridin-2-on vegyületek
AU2017219847B2 (en) 2016-02-19 2021-02-04 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes
WO2018144791A1 (en) * 2017-02-03 2018-08-09 Millennium Pharmaceuticals, Inc. Combination of vps34 inhibitors and mtor inhibitors
GB201706327D0 (en) * 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
KR102730753B1 (ko) * 2017-08-23 2024-11-18 스프린트 바이오사이언스 아베 피리딘아민-피리돈 및 피리미딘아민-피리돈 화합물
SI3672967T1 (sl) 2017-08-23 2022-04-29 Sprint Bioscience Ab Spojine azaindolilpiridona in diazaindolilpiridona
PT3672962T (pt) 2017-08-23 2022-04-12 Sprint Bioscience Ab Compostos de morfolinilpiridona
ES2910839T3 (es) 2017-08-23 2022-05-13 Sprint Bioscience Ab Compuestos de piridilpiridona
BR112020004441B1 (pt) 2017-09-18 2024-01-16 Basf Se Compostos da fórmula i, composição agroquímica, semente revestida, uso de compostos e método não-terapêutico de combate de fungos
BR102019002873A2 (pt) 2018-02-13 2019-09-10 Gilead Sciences Inc inibidores de pd-1/pd-l1
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020045941A1 (ko) * 2018-08-27 2020-03-05 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
US20220324830A1 (en) * 2019-09-11 2022-10-13 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
CN112574207B (zh) * 2019-09-30 2023-04-11 南京药石科技股份有限公司 Erk1/2蛋白激酶抑制剂及其用途
EP4105216A4 (en) * 2020-02-13 2024-02-28 Genfleet Therapeutics (Shanghai) Inc. DIHYDRONAPHTHYRIDINONE COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL USE THEREOF
JP2023553809A (ja) 2020-11-25 2023-12-26 デシフェラ・ファーマシューティカルズ，エルエルシー ウイルス感染の治療に使用するためのｖｓｐ３４阻害剤としてのピリジルピリドン誘導体
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
EP4444429A1 (en) 2021-12-09 2024-10-16 Deciphera Pharmaceuticals, LLC Raf kinase inhibitors and methods of use thereof
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
GB202216324D0 (en) * 2022-11-02 2022-12-14 Cerevance Ltd Novel compounds

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454378T1 (de) 2002-11-01 2010-01-15 Vertex Pharma Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
GB0425026D0 (en) * 2004-11-12 2004-12-15 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
EP1814856A1 (en) 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
CN101111479A (zh) * 2004-12-16 2008-01-23 沃泰克斯药物股份有限公司 可用作激酶抑制剂的吡啶酮
KR20070095952A (ko) * 2004-12-16 2007-10-01 버텍스 파마슈티칼스 인코포레이티드 염증성 질환, 증식성 질환 및 면역학적으로 매개된 질환치료용 Ｔｅｃ 계열 단백질 키나제의 억제제로서 유용한피리드-2-온
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US20090306126A1 (en) 2006-05-22 2009-12-10 Astrazeneca Ab Indole Derivatives
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
WO2008025821A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
NZ578159A (en) 2006-12-04 2012-01-12 Astrazeneca Ab Antibacterial polycyclic urea compounds
EA200900799A1 (ru) 2006-12-22 2009-12-30 Новартис Аг Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
CN101765591B (zh) 2007-07-26 2013-11-27 诺华股份有限公司 用于治疗炎性或过敏性病症的嘧啶衍生物
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
EP2217590A4 (en) 2007-09-17 2011-12-14 Glaxosmithkline Llc Pyridopyrimidine derivatives as PI3-kinase inhibitors
US20100311736A1 (en) * 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
PE20091268A1 (es) 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2010008847A2 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
AU2009279787B2 (en) 2008-08-04 2014-05-29 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA018824B1 (ru) 2008-11-11 2013-10-30 Эли Лилли Энд Компани КОМБИНИРОВАННАЯ ТЕРАПИЯ ИНГИБИТОРОМ КИНАЗЫ p70 S6 И ИНГИБИТОРОМ mTOR
WO2010057877A1 (en) * 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
TW201026695A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Piperidine compounds and uses thereof-596
BRPI1010974A2 (pt) 2009-05-22 2019-09-24 Exelixis Inc benzoxazepinas baseada em inibidores p13k/ m tor contra doenças proliferativas
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
JP2011033670A (ja) * 2009-07-30 2011-02-17 Sony Corp 光学ファインダユニットおよび撮像装置
WO2011026911A1 (en) * 2009-09-04 2011-03-10 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
SG182803A1 (en) * 2010-02-05 2012-09-27 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
EA201300080A1 (ru) 2010-07-05 2013-06-28 Мерк Патент Гмбх Дипиридильные производные, пригодные для лечения заболеваний, индуцированных киназами
ES2550939T3 (es) 2010-07-16 2015-11-13 Nivalis Therapeutics, Inc. Nuevos compuestos de dihidropiridin-2-(1H)-ona como inhibidores de la S-nitrosoglutatión reductasa y antagonistas del receptor de la neurocinina-3
WO2012015723A1 (en) 2010-07-26 2012-02-02 Bristol-Myers Squibb Company Sulfonamide compounds useful as cyp17 inhibitors
TW201217365A (en) 2010-08-11 2012-05-01 Millennium Pharm Inc Heteroaryls and uses thereof
US8478700B2 (en) 2010-08-11 2013-07-02 Brightedge Technologies, Inc. Opportunity identification and forecasting for search engine optimization
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
EA201390717A1 (ru) 2010-11-17 2013-10-30 Новартис Аг 3-(аминоарил)пиридиновые соединения
WO2012085815A1 (en) 2010-12-21 2012-06-28 Novartis Ag Bi-heteroaryl compounds as vps34 inhibitors
SI2655375T1 (sl) 2010-12-23 2015-03-31 Sanofi Derivati pirimidinona, njihova priprava in njihova farmacevtska uporaba
UY33874A (es) * 2011-01-26 2012-08-31 Sanofi Aventis Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas
US20130303507A1 (en) 2011-01-28 2013-11-14 Novartis Ag Substituted hetero-biaryl compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
DE102011077104A1 (de) 2011-06-07 2012-12-13 Siemens Aktiengesellschaft Verfahren zur Gewinnung von metallhaltigen Wertstoffen aus einem metallhaltige Wertstoffe enthaltenden suspensionsartigen Massestrom
KR101502500B1 (ko) 2011-07-01 2015-03-16 주식회사 엘지화학 비수 전해액 및 이를 이용한 리튬 이차전지
UA111382C2 (uk) * 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази
JP2015503504A (ja) 2011-12-23 2015-02-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヘテロアリールおよびその使用
JP6302846B2 (ja) 2012-02-22 2018-03-28 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用
CA2873861C (en) * 2012-04-05 2021-01-19 Boehringer Ingelheim International Gmbh Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
WO2014053533A1 (en) * 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
EP2903613B1 (en) 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of irak4 activity
WO2014083327A1 (en) 2012-11-27 2014-06-05 Md Pharma Ab Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
RU2655604C2 (ru) * 2013-01-11 2018-05-29 Фуджифилм Корпорэйшн Азотсодержащее гетероциклическое соединение или его соль
CN105189481A (zh) 2013-03-13 2015-12-23 艾伯维公司 吡啶cdk9激酶抑制剂
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
ES2908042T3 (es) 2014-01-14 2022-04-27 Takeda Pharmaceuticals Co Heteroarilos y usos de los mismos
EP3094326A4 (en) 2014-01-14 2017-07-26 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2016038582A1 (en) * 2014-09-12 2016-03-17 Novartis Ag Compounds and compositions as raf kinase inhibitors
UY36294A (es) * 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12227498B2 (en) 2018-08-27 2025-02-18 Daewoong Pharmaceutical Co., Ltd. Heterocyclic amine derivative and pharmaceutical composition comprising same
RU2809869C1 (ru) * 2020-02-13 2023-12-19 Генфлит Терапьютикс (Шанхай) Инк. Соединение на основе дигидронафтиридинона, и способ его получения, и его применение в медицине

Also Published As

Publication number Publication date
UY35951A (es) 2015-07-31
US10538533B2 (en) 2020-01-21
GEP20196983B (en) 2019-06-25
JP6609258B2 (ja) 2019-11-20
PH12016501388A1 (en) 2016-08-15
US20180118762A1 (en) 2018-05-03
CL2016001805A1 (es) 2017-07-07
EP3094325A1 (en) 2016-11-23
ES2908042T3 (es) 2022-04-27
CN105916503B (zh) 2020-04-14
MX2016009135A (es) 2016-10-05
US20170073326A1 (en) 2017-03-16
JP2017503813A (ja) 2017-02-02
CR20160363A (es) 2016-10-12
TN2016000270A1 (en) 2017-10-06
WO2015108861A1 (en) 2015-07-23
MY182908A (en) 2021-02-05
TW201613865A (en) 2016-04-16
TWI662024B (zh) 2019-06-11
IL246755A0 (en) 2016-08-31
US9802960B2 (en) 2017-10-31
US9751854B2 (en) 2017-09-05
CA2935867A1 (en) 2015-07-23
KR20160122736A (ko) 2016-10-24
EA032458B1 (ru) 2019-05-31
PE20161313A1 (es) 2016-12-17
US20150225422A1 (en) 2015-08-13
EP3094325A4 (en) 2017-08-09
BR112016016289B1 (pt) 2023-02-07
AP2016009368A0 (en) 2016-08-31
CN105916503A (zh) 2016-08-31
SG11201604820XA (en) 2016-07-28
BR112016016289A2 (pt) 2018-05-08
EP3094325B1 (en) 2021-10-13
CA2935867C (en) 2023-04-04
ECSP16067303A (es) 2017-02-24
DOP2016000173A (es) 2016-12-15
AU2015206652A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
EA201691421A1 (ru) Гетероарилы и их применение
IL292644A (en) Ras inhibitors
LT3710446T (lt) Junginiai, naudingi cdk7 slopinimui
EA201591509A1 (ru) Ингибиторы cdc7
EA201790108A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
HUE049591T2 (hu) Makrociklusos MCL-1 inhibitorok rák kezelésére
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
HRP20181661T1 (hr) Inhibitori jak1 za liječenje mijelodisplastičnih sindroma
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CY1121444T1 (el) Παραγωγα κιnoλonης ως αναστoλεις υποδοχεα αυξητικου παραγοντα ινοβλαστων
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
HUE062158T2 (hu) EZH2 inhibitorok a limfóma kezelésére
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
IL261015A (en) History of methylamine as lysis oxidase inhibitors for cancer treatment
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
EA201791684A1 (ru) Селективные ингибиторы bace1
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

PC4A Registration of transfer of a eurasian patent by assignment